ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer

scientific article published on 03 March 2020

ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/0008-5472.CAN-19-3126
P932PMC publication ID7272301
P698PubMed publication ID32127357

P50authorAtish D. ChoudhuryQ58403143
David LiuQ59751039
Haitham ElmarakebyQ86928276
Jihye ParkQ88032960
William C HahnQ88192808
P2093author name stringBose S Kochupurakkal
Eliezer M Van Allen
Steven P Balk
Mu-Yan Cai
Justin H Hwang
Kent W Mouw
Shahrzad Rafiei
Cora Ricker
Kenyon Fitzpatrick
P2860cites workThe PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.Q27851580
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell linesQ27853007
Integrative clinical genomics of advanced prostate cancerQ27853170
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerQ27853235
FirebrowseR: an R client to the Broad Institute's Firehose PipelineQ28583991
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53Q36238650
Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinaseQ36747534
Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitorsQ37119667
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate CancerQ37179254
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencingQ37264357
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor OlaparibQ37633188
A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-functionQ38955450
A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivityQ40595505
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.Q46518098
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid TumorsQ49679908
ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.Q50862844
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.Q50913049
The long tail of oncogenic drivers in prostate cancer.Q52611753
Genomic Hallmarks and Structural Variation in Metastatic Prostate CancerQ58593960
Measuring recombination proficiency in mouse embryonic stem cellsQ80902088
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM MutationsQ91854863
P577publication date2020-03-03
P1433published inCancer ResearchQ326097
P1476titleATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer

Reverse relations

cites work (P2860)
Q101237469Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
Q97681296The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go

Search more.